Tier 2 — strong
The efficacy of coenzyme Q10 treatment in alleviating the symptoms of primary coenzyme Q10 deficiency: A systematic review
Journal of Cellular and Molecular Medicine
2022
26(17):4635-4644
Bibliography
- PubMed
- PMID 35985679
- PubMed Central
- PMC9443948
- Funding
- Detailed funding is reported in the full text; the PubMed abstract does not summarize it.
- Competing interests
- Detailed disclosures are reported in the full text; the PubMed abstract does not summarize them.
Study snapshot
| Design | Systematic review of primary CoQ10-deficiency case reports and series |
|---|---|
| Model | Genetically defined primary CoQ10 deficiency |
| Sample | 303 patients identified; 89 evaluable treated cases; 24 reported improvement |
| Intervention | Oral CoQ10 replacement therapy |
| Duration | Varied widely across reports |
| Endpoints | Overall symptomatic response; Ataxia; Proteinuria; Partial symptom-specific improvement; Response after stopping therapy |
What the study showed, in plain terms
Key findings
What this study can and cannot tell us
Citation network
Articles citing this research paper
Biohack Blueprint analyses that reference this study in their evidence base.
- CoQ10 and Mitochondrial Dysfunction: What Human Evidence ShowsDoes CoQ10 help mitochondrial dysfunction? Separate primary genetic CoQ10 deficiency from broader mitochondrial disease, with randomized evidence, dose and limitations.Read analysis
- CoQ10 Benefits: What Human Studies Actually ShowCoQ10 benefits ranked by human evidence: heart failure, migraine, fatigue, blood pressure, metabolism, fertility, statins, exercise and where claims remain unproven.Read analysis
Editorial review
Reviewed by the Biohack Blueprint research team
Last verified
